This has been explored preclinically, where the addition of PD-L1 blockade to mIDHi showed significant therapeutic advantages in an IDH-mutant mouse glioma model by promoting the generation of memory CD8+ T cells and mitigating T cell exhaustion [43]. The gene discussed is CD274; the disease is glioma.